Skip to content
DataLookout
Menu

DARA-AA-001NCT07287228

The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 22 words
    • Start date changed from estimate of Dec 10, 2025 to Dec 17, 2025
    • Study description revised
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Overall response rate
Timeframe: Within 12 weeks after treatment

Secondary (1)

Incidence of adverse events

Arms and interventions

After enrollment, patients will receive daratumumab treatment.Experimental

This study is designed as a seamless Phase Ib/II trial. The target population is adult patients with refractory aplastic anemia (AA), who must meet the criteria for refractory AA at enrollment. After enrollment, patients will receive daratumumab treatment.

Drugs: Daratumumab

Sites

1 site in 1 country

  • Institute of Hematology & Blood Diseases Hosptial, Chinese Academy of Medical Science and Peking Union Medical SchoolTianjin, Tianjin Municipality, China